Genetic Predisposition Clinical Trial
Official title:
Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"
Verified date | October 2022 |
Source | University Hospital Tuebingen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and the healthy parents of those affected for trio analysis (N in total 1350).
Status | Completed |
Enrollment | 1350 |
Est. completion date | October 1, 2022 |
Est. primary completion date | October 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Unclear molecular cause of the disease - Suspected genetic cause of the disease - Healthy parents of those affected for trio analysis Cohort 1: IQ < 70 with and without malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa, achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3: Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract, tumours of the salivary gland and pancreatic tumors in children. Exclusion Criteria: Cohort 1: Toxic causes (drugs, infections) Cohort 2: patients with non-genetic forms of blindness Cohort 3: adult cancer, blood cancer - Missing informed consent of the patient/ legal guardian - Missing samples of both parents - Previous WES or panel analysis- |
Country | Name | City | State |
---|---|---|---|
Germany | University Hospital Tübingen | Tübingen |
Lead Sponsor | Collaborator |
---|---|
University Hospital Tuebingen |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Full genomic sequence analysis carried out by Whole Genome Sequencing (WGS) | Number of genomic variants in disease and health parents by WGS (a Next-Generation Sequencing Technology, NGS) | Day 1 | |
Secondary | Genome sequencing | Verification of the genetic causes of unclear genetic diseases by clinical genome sequencing | Day 1 | |
Secondary | De novo alterations | Number of de novo alterations in genome of the enrolled population | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04746794 -
Early Detection of GEnetic Risk (EDGE)
|
N/A | |
Completed |
NCT03792685 -
Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention
|
N/A | |
Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
Not yet recruiting |
NCT06441942 -
Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
|
||
Terminated |
NCT04119596 -
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
|
||
Recruiting |
NCT04141462 -
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
|
N/A | |
Completed |
NCT02826330 -
Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
|
||
Recruiting |
NCT05929976 -
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
|
||
Not yet recruiting |
NCT04620278 -
Genetic Investigation of Cancer Predisposition
|
||
Active, not recruiting |
NCT02373709 -
Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
|
||
Not yet recruiting |
NCT06089421 -
Genetic Information Assistant in Telegenetics
|
N/A | |
Completed |
NCT05975489 -
Genetics in the Effect of Caffeine on Fat Oxidation
|
N/A | |
Completed |
NCT04113239 -
Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
|
||
Enrolling by invitation |
NCT04373525 -
Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
|
||
Completed |
NCT03362099 -
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)
|
Phase 4 | |
Recruiting |
NCT05857670 -
Psyco Quality of Life and Procreation BRCA1/2
|
||
Active, not recruiting |
NCT04774445 -
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
|
N/A | |
Recruiting |
NCT05759143 -
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
|
N/A | |
Active, not recruiting |
NCT04920513 -
Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
|
||
Active, not recruiting |
NCT04781205 -
Genome Driven Primary Care Clinics - an RCT
|
N/A |